Pfizer Inc.  

(Public, NYSE:PFE)   Watch this stock  
Find more results for PFE
30.44
0.00 (0.00%)
Nov 20 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 30.25 - 30.49
52 week 27.51 - 32.96
Open 30.33
Vol / Avg. 0.00/25.83M
Mkt cap 192.20B
P/E 19.25
Div/yield 0.26/3.42
EPS 1.58
Shares 6.30B
Beta 0.68
Inst. own 72%
Jan 26, 2015
Q4 2014 Pfizer Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 17, 2014
Pfizer Immuno-Oncology Strategic Alliance Announcement - Webcast
Nov 17, 2014
Merck KGaA Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology
Nov 17, 2014
Merck KGaA Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology Journalist Call
Nov 12, 2014
Pfizer Inc at Credit Suisse Healthcare Conference
Oct 28, 2014
Q3 2014 Pfizer Inc Earnings Call
Oct 28, 2014
Q3 2014 Pfizer Inc Earnings Release
Sep 10, 2014
Pfizer Inc at Morgan Stanley Healthcare Conference
Sep 3, 2014
Protalix Biotherapeutics Inc Corporate Call to Discuss ELELYSO Pediatric Approval and Provide Updates on Additional Programs - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 21.65% 22.12%
Operating margin 30.26% 31.32%
EBITD margin - 45.80%
Return on average assets 6.24% 6.38%
Return on average equity 13.85% 14.45%
Employees 77,700 -
CDP Score - 91 B

Address

235 E 42ND ST
NEW YORK, NY 10017
United States - Map
+1-212-5732323 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company�s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Its Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. Primary Care operating segment includes revenues from human prescription pharmaceutical products primarily prescribed by primary-care physicians. In November 2012, the Company acquired NextWave Pharmaceuticals, Inc. On November 30, 2012, the Company completed the sale of its Nutrition business.

Officers and directors

Ian C. Read Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Frank A. D'Amelio Chief Financial Officer, Executive Vice President - Business Operations
Age: 56
Bio & Compensation  - Reuters
Albert Bourla Group President - Vaccines, Oncology and Consumer Healthcare Business
Age: 52
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. President - Worldwide Research and Development
Age: 55
Bio & Compensation  - Reuters
Geno J. Germano Group President - Global Innovative Pharma Business
Age: 53
Bio & Compensation  - Reuters
John D. Young Group President - Global Established Pharma Business
Age: 49
Bio & Compensation  - Reuters
Rady A. Johnson Executive Vice President, Chief Compliance and Risk Officer
Age: 52
Bio & Compensation  - Reuters
Douglas M. Lankler Executive Vice President, General Counsel
Age: 48
Bio & Compensation  - Reuters
Charles H. Hill III Executive Vice President - Worldwide Human Resources
Age: 58
Bio & Compensation  - Reuters
Freda C. Lewis-Hall M.D. Executive Vice President, Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters